Somatropin · Serostim

Protein / enzyme therapeutic

Approvedregulatory verdict

Evidence outlook

Approved: HIV

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
CA
  • Treatment of HIV wasting associated with catabolism, weight loss or cachexia (Serostim 5 mg/vial)
pdf.hres.ca

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (5)
HIV
NCT01077960 · EMD Serono
2005-02 – 2006-01 · Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
What this study did
NCT00082628 · EMD Serono
2004-05-28 – 2005-09-28 · HIV Infections, Lipodystrophy
What this study did
Other / comorbidity
NCT01237340 · EMD Serono
2010-10 – 2011-12 · Growth Hormone Deficiency (GHD)
What this study did
NCT00109733 · EMD Serono
2005-01 – 2006-07 · Childhood-onset Growth Hormone Deficiency, Pituitary Dwarfism
What this study did
Phase 2/3 (2)
HIV
NCT00294918 · EMD Serono
2001-09 – 2003-02 · Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS), Human Immunodeficiency Virus Infections
What this study did
NCT00294164 · EMD Serono
2001-03 – 2002-05 · Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS), Human Immunodeficiency Virus Infections
What this study did
Phase 2 (1)
HIV
NCT00071240 · National Institute of Allergy and Infectious Diseases (NIAID)
2002-10 – 2007-09 · HIV Infections
What this study did
Phase 1 (2)
Other / comorbidity
NCT03123913 · University of Rochester
2017-12-18 – 2022-03-28 · Facioscapulohumeral Muscular Dystrophy
What this study did
NCT00407472 · EMD Serono
2005-09 – 2005-09 · Healthy
What this study did
Phase 4 (2)
Other / comorbidity
NCT01806298 · Merck KGaA, Darmstadt, Germany
2013-06 – 2016-03 · Adult Growth Hormone Deficiency
What this study did
NCT01187550 · Merck KGaA, Darmstadt, Germany
2007-03 – 2009-04 · Dwarfism, Pituitary
What this study did
Used as active comparator (12)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (6)
Other / comorbidity
NCT07221851 · Ascendis Pharma A/S
2025-12-12 – 2029-03 · Turner Syndrome, Short Stature Homeobox Gene Mutation, Idiopathic Short Stature, Small for Gestational Age at Delivery
What this study did
NCT02968004 · OPKO Health, Inc.
2016-12 – 2024-05 · Pediatric Growth Hormone Deficiency
What this study did
NCT04615273 · Ascendis Pharma Endocrinology Division A/S
2020-12-03 – 2023-12-01 · Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
What this study did
NCT04326374 · Visen Pharmaceuticals (Shanghai) Co., Ltd.
2019-12-30 – 2022-04 · Growth Hormone Deficiency, Endocrine System Diseases, Hormones, Pituitary Diseases, Pituitary Disease, Anterior
What this study did
NCT02229851 · Novo Nordisk A/S
2014-10-31 – 2018-05-07 · Growth Hormone Disorder, Adult Growth Hormone Deficiency
What this study did
NCT02382939 · Novo Nordisk A/S
2015-02-12 – 2016-01-04 · Adult Growth Hormone Deficiency, Growth Hormone Disorder
What this study did
Phase 2 (5)
Other / comorbidity
NCT05690386 · Ascendis Pharma Endocrinology Division A/S
2023-02-15 – 2027-12 · Turner Syndrome
What this study did
NCT02092077 · Teva Pharmaceutical Industries, Ltd.
2014-04-30 – 2016-08-31 · Growth Hormone-Deficiency
What this study did
NCT01947907 · Ascendis Pharma A/S
2013-07 – 2015-09 · Growth Hormone Deficiency (GHD)
What this study did
NCT01592500 · OPKO Health, Inc.
2012-02 – 2015-07 · Pediatric Growth Hormone Deficiency
What this study did
NCT00936403 · Novo Nordisk A/S
2009-08 – 2010-07 · Growth Hormone Disorder, Growth Hormone Deficiency in Children
What this study did
Phase 1 (1)
Other / comorbidity
Appears in other studies (109)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (45)
Other / comorbidity
NCT06103513 · Northwell Health
2023-12-10 – 2028-01-05 · Growth Disorders, Growth Failure, Growth Hormone Treatment, Growth
What this study did
NCT04697381 · Pfizer
2021-02-09 – 2024-04-15 · Prader-Willi Syndrome
What this study did
NCT03554265 · The University of Texas Medical Branch, Galveston
2018-08-06 – 2023-10-04 · Traumatic Brain Injury, Fatigue, Cognitive Impairment, COVID-19
What this study did
NCT01927861 · Novo Nordisk A/S
2013-08-19 – 2018-07-12 · Genetic Disorder, Noonan Syndrome
What this study did
NCT00355030 · Eli Lilly and Company
2006-06 – 2015-07 · Idiopathic Short Stature (ISS)
What this study did
NCT01778023 · Novo Nordisk A/S
2013-01-17 – 2014-12-17 · Growth Disorder, Idiopathic Short Stature
What this study did
NCT00163189 · Pfizer
2005-01 – 2014-12 · Growth Hormone Deficiency
What this study did
NCT00271518 · LG Life Sciences
2005-09 – 2013-12 · Growth Hormone Deficiency (GHD)
What this study did
NCT00627523 · Pfizer
2008-02 – 2013-12 · Infant, Small for Gestational Age
What this study did
NCT00943995 · Nationwide Children's Hospital
2010-07 – 2012-08 · Kidney Failure, Chronic, Renal Dialysis
What this study did
NCT04420481 · Göteborg University
2004-04-28 – 2012-02-25 · Heart Failure, Systolic, Ischemic Heart Disease Chronic
What this study did
NCT00174291 · Pfizer
2002-03 – 2011-10 · Endocrine System Diseases
What this study did
NCT00163215 · Pfizer
2005-01 – 2011-10 · Endocrine System Diseases
What this study did
NCT00174187 · Pfizer
2000-09 – 2011-09 · Endocrine System Diseases
What this study did
NCT00625872 · Pfizer
2008-07 – 2011-03 · Growth Hormone Therapy, Infant, Small for Gestational Age
What this study did
NCT00190658 · Eli Lilly and Company
2000-02 – 2010-09 · Failure to Thrive
What this study did
NCT00452491 · Sanofi
1993-05 – 2010-04 · Fetal Growth Retardation
What this study did
NCT00184717 · Novo Nordisk A/S
2004-08-18 – 2009-12-28 · Foetal Growth Problem, Small for Gestational Age
What this study did
NCT00174252 · Pfizer
2005-02 – 2009-04 · Fetal Growth Retardation
What this study did
NCT00503698 · Novo Nordisk A/S
2007-07 – 2008-12 · Chronic Kidney Disease, End-Stage Renal Disease
What this study did
NCT00630487 · Pfizer
2008-05 – 2008-10 · Growth Hormone Deficiency
What this study did
NCT01529944 · Novo Nordisk A/S
2008-09 – 2008-10 · Genetic Disorder, Noonan Syndrome
What this study did
NCT00234533 · Ipsen
2004-06 – 2008-07 · Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases, Dwarfism
What this study did
NCT00191165 · Eli Lilly and Company
2004-03 – 2008-04 · Growth Hormone Deficiency
What this study did
NCT00191113 · Eli Lilly and Company
1989-02 – 2007-12 · Turner Syndrome
What this study did
NCT00191529 · Eli Lilly and Company
2002-12 – 2007-06 · Infant, Small for Gestational Age
What this study did
NCT00102817 · Novo Nordisk A/S
2003-05 – 2006-12 · Growth Hormone Disorder, Pituitary Dwarfism
What this study did
NCT00174278 · Pfizer
1997-02 – 2006-10 · Growth Hormone Deficiency, Growth Retardation
What this study did
NCT00184730 · Novo Nordisk A/S
2004-11 – 2006-09 · Growth Hormone Disorder, Adult Growth Hormone Deficiency
What this study did
NCT00184678 · Novo Nordisk A/S
2002-02 – 2006-07 · Growth Hormone Disorder, Adult Growth Hormone Deficiency
What this study did
NCT00184756 · Novo Nordisk A/S
2002-11 – 2006-07 · Foetal Growth Problem, Small for Gestational Age
What this study did
NCT00191360 · Eli Lilly and Company
2003-01 – 2006-05 · Adult Growth Hormone Deficiency
What this study did
NCT00191074 · Eli Lilly and Company
2001-02 – 2006-01 · Growth Disorder
What this study did
NCT00184743 · Novo Nordisk A/S
2003-12-06 – 2005-12-28 · Growth Hormone Disorder, Adult Growth Hormone Deficiency
What this study did
NCT01529840 · Novo Nordisk A/S
1990-06 – 2005-09 · Genetic Disorder, Noonan Syndrome
What this study did
NCT00557336 · Novo Nordisk A/S
2003-07-28 – 2005-06-29 · Foetal Growth Problem, Small for Gestational Age
What this study did
NCT00184691 · Novo Nordisk A/S
1999-04 – 2005-06 · Foetal Growth Problem, Small for Gestational Age
What this study did
NCT00519558 · Novo Nordisk A/S
2003-05-31 – 2005-01-24 · Growth Hormone Disorder, Adult Growth Hormone Deficiency
What this study did
NCT02693522 · Daewoong Pharmaceutical Co. LTD.
2003-10 – 2004-12 · Growth Hormone Deficiency
What this study did
NCT00262249 · Novo Nordisk A/S
2000-08 – 2004-05 · Growth Hormone Disorder, Growth Hormone Deficiency in Children, Growth Disorder, Idiopathic Short Stature
What this study did
NCT01518036 · Novo Nordisk A/S
1987-09-14 – 2004-04-11 · Genetic Disorder, Turner Syndrome
What this study did
NCT00406926 · Eli Lilly and Company
1999-08 – 2003-08 · Turner Syndrome
What this study did
NCT01502124 · Novo Nordisk A/S
2001-05-08 – 2003-03-05 · Growth Hormone Disorder, Growth Hormone Deficiency in Children
What this study did
NCT01563926 · Novo Nordisk A/S
2000-10-23 – 2002-10-10 · Growth Hormone Disorder, Growth Hormone Deficiency in Children, Genetic Disorder, Turner Syndrome
What this study did
NCT00570011 · Eli Lilly and Company
1997-06 – 1998-12 · Growth Hormone Deficiency
What this study did
Phase 2/3 (4)
Other / comorbidity
NCT05900661 · Beni-Suef University
2023-07-30 – 2023-09-30 · Poor Responders
What this study did
NCT03038594 · The University of Texas Medical Branch, Galveston
2015-11-01 – 2021-11-30 · Burns, Growth Hormone Treatment
What this study did
NCT00748969 · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
2008-11 – 2013-09 · Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
What this study did
NCT00511329 · Nationwide Children's Hospital
2007-08 – 2010-05 · Arthritis, Juvenile Rheumatoid, Crohn Disease
What this study did
Phase 2 (17)
Other / comorbidity
NCT05382637 · Children's National Research Institute
2022-08-26 – 2028-09-01 · Growth Disorders
What this study did
NCT03104010 · Changchun GeneScience Pharmaceutical Co., Ltd.
2017-04 – 2022-09 · Adult Growth Hormone Deficiency
What this study did
NCT02597660 · Hospital for Special Surgery, New York
2020-05-01 – 2020-12-01 · Tendinopathy
What this study did
NCT02326610 · Tel-Aviv Sourasky Medical Center
2014-12 – 2018-12 · Infant, Small for Gestational Age, Growth Hormone Treatment, Infant, Premature, Diseases
What this study did
NCT02420353 · University of Michigan
2015-05 – 2018-10 · Rupture of Anterior Cruciate Ligament
What this study did
NCT03189160 · Changchun GeneScience Pharmaceutical Co., Ltd.
2016-03 – 2018-03 · Turner Syndrome
What this study did
NCT01298960 · Fundacion Dexeus
2011-02 – 2013-06 · Complications; Artificial Fertilization, Introduction of Embryo in Embryo Transfer
What this study did
NCT00572156 · Ipsen
2007-12 – 2012-03 · Insulin-like Growth Factor-1 Deficiency
What this study did
NCT00488124 · University of Erlangen-Nürnberg Medical School
2005-11 – 2011-03 · Idiopathic Short Stature
What this study did
NCT00837863 · Altus Pharmaceuticals
2009-03 – 2010-09 · Growth Hormone Deficiency
What this study did
NCT00080483 · University of Pennsylvania
2004-03 – 2010-09 · Hypopituitarism, Hypogonadism, Growth Hormone Deficiency
What this study did
NCT00635960 · Federico II University
2007-03 – 2010-05 · Amyotrophic Lateral Sclerosis
What this study did
NCT00174460 · Pfizer
2005-08 – 2010-03 · Growth Hormone Therapy, Infant, Very Low Birth Weight
What this study did
NCT00079742 · Genentech, Inc.
2003-09 – 2007-05 · Cystic Fibrosis
What this study did
NCT01342146 · Changchun GeneScience Pharmaceutical Co., Ltd.
2006-05 – 2007-02 · Growth Hormone Deficiency
What this study did
NCT00184652 · Novo Nordisk A/S
2003-04 – 2005-09 · Chronic Kidney Disease, End-Stage Renal Disease
What this study did
NCT00254514 · Novo Nordisk A/S
2001-08 – 2003-10 · Bone Fracture, Tibia Fractures
What this study did
Phase 1 (15)
Other / comorbidity
NCT02726542 · Massachusetts General Hospital
2017-05-03 – 2020-04-02 · NAFLD
What this study did
NCT04042428 · Parc de Salut Mar
2019-10-25 – 2020-01-08 · Healthy Volunteers
What this study did
NCT03800810 · Universitas Indonesia
2015-05 – 2019-05 · Osteoarthritis, Knee
What this study did
NCT01512095 · Novo Nordisk A/S
2013-08 – 2013-11 · Growth Disorder, Healthy
What this study did
NCT01339182 · Xiamen Amoytop Biotech Co., Ltd.
2011-01 – 2012-08 · Healthy
What this study did
NCT01440686 · HanAll BioPharma Co., Ltd.
2011-09 – 2012-01 · Growth Hormone Deficiency
What this study did
NCT01401244 · Novo Nordisk A/S
2011-07-14 – 2011-09-27 · Genetic Disorder, Prader-Willi Syndrome, Growth Disorder, Idiopathic Short Stature, Healthy
What this study did
NCT01613573 · Changchun GeneScience Pharmaceutical Co., Ltd.
2010-03 – 2010-11 · Growth Hormone Deficiency
What this study did
NCT00473187 · University of Rostock
2004-08 – 2009-08 · Hypophosphatemic Rickets, Growth Disorders, Somatropin Therapy
What this study did
NCT00455260 · Teva Neuroscience, Inc.
2007-04 – 2007-10 · Growth Hormone Deficiency
What this study did
NCT01502137 · Novo Nordisk A/S
2005-06 – 2005-11 · Chronic Kidney Disease, End-Stage Renal Disease, Healthy
What this study did
NCT00470002 · Hannover Medical School
2004-05 – 2005-01 · Cardiovascular Disease
What this study did
NCT00931476 · Novo Nordisk A/S
2000-04-06 – 2000-06-08 · Growth Hormone Disorder, Adult Growth Hormone Deficiency, Healthy
What this study did
Phase 4 (21)
Other / comorbidity
NCT06448195 · Shanghai Zhongshan Hospital
2023-01-01 – 2025-12-31 · Growth Hormone Treatment
What this study did
NCT00840944 · Belgian Study Group for Pediatric Endocrinology
2008-01 – 2024-04 · Idiopathic Short Stature
What this study did
NCT03759301 · ClinAmygate
2018-12-20 – 2019-06-05 · Infertility, Female
What this study did
NCT03015909 · LG Life Sciences
2016-08-11 – 2017-12-21 · Short Stature, Idiopathic, Infant, Small for Gestational Age, Growth Hormone Deficiency, Chronic Renal Failure, Turner Syndrome
What this study did
NCT01859949 · Pfizer
2002-10 – 2015-08 · Short Stature Born Small for Gestational Age (SGA)
What this study did
NCT00432263 · Pfizer
started 2007-04 · Brain Injuries
What this study did
NCT01380366 · Northwestern University
2006-10 – 2015-02 · Short Bowel Syndrome
What this study did
NCT01438801 · Ipsen
2013-05 – 2013-05-31 · Idiopathic Short Stature
What this study did
NCT01052623 · Johann Wolfgang Goethe University Hospital
2010-01 – 2012-09 · Ataxia Telangiectasia, Growth Failure
What this study did
NCT00519844 · Novo Nordisk A/S
2005-07 – 2006-01 · Foetal Growth Problem, Small for Gestational Age
What this study did
NCT00184769 · Novo Nordisk A/S
1998-01-29 – 2005-12-21 · Chronic Kidney Disease, Chronic Renal Insufficiency
What this study did
NCT01697644 · Novo Nordisk A/S
1990-10 – 2005-05 · Foetal Growth Problem, Small for Gestational Age
What this study did
NCT00567385 · Novo Nordisk A/S
2003-03-10 – 2004-03-22 · Growth Hormone Disorder, Growth Hormone Deficiency in Children
What this study did
NCT00638053 · Pfizer
2002-11 – 2003-11 · Brain Injuries, Growth Hormone Deficiency Dwarfism
What this study did
NCT01518062 · Novo Nordisk A/S
1989-11 – 2003-09 · Genetic Disorder, Turner Syndrome
What this study did
NCT01734486 · Novo Nordisk A/S
1996-09-23 – 2003-05-21 · Genetic Disorder, Turner Syndrome
What this study did
NCT01734447 · Novo Nordisk A/S
2000-04-30 – 2003-04-30 · Foetal Growth Problem, Small for Gestational Age
What this study did
NCT01562834 · Novo Nordisk A/S
1998-10-21 – 2002-12-01 · Growth Hormone Disorder, Adult Growth Hormone Deficiency
What this study did
NCT01698944 · Novo Nordisk A/S
2001-05-16 – 2002-11-18 · Growth Hormone Disorder, Adult Growth Hormone Deficiency
What this study did
NCT00490191 · Eli Lilly and Company
1999-01 – 2001-07 · Hypopituitarism
What this study did
Early phase / not applicable (7)
HIV
NCT00050921 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2005-03 · HIV Infections
What this study did
NCT00006143 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 2002-07 · HIV Infections
What this study did
Other / comorbidity
NCT04588844 · Shandong University
2020-12-01 – 2023-03-20 · Poor Ovarian Reserve
What this study did
NCT02655263 · University of Aarhus
2016-01 – 2017-10 · Healthy
What this study did
NCT00969644 · Herlev Hospital
2009-09 – 2010-03 · Interaction Between the GH/IGF-I System and the Immune-system
What this study did
NCT00476879 · University of Aarhus
2006-08 – 2008-06 · Metabolism, Fatty Liver
What this study did
NCT00136032 · Massachusetts General Hospital
2002-01 – 2006-11 · Growth Hormone Deficiency
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for HIV: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Somatropin (Serostim): this drugApprovedProtein / enzyme therapeuticGrowth hormone receptorPartial signal
NCT00082628: Change in visceral adipose tissue area at Week 12: -32.6 cm² Serostim (n=210) vs 0.5 cm² placebo (n=74), p<0.001. phase 3 result · pivotal pending
NCT01077960: Primary endpoint: mean change in trunk fat from baseline to week 12, -1.7 kg (SD 1.4; n=106; p<0.001). phase 3 result · pivotal pending
Amprenavir
ApprovedUS marketing discontinued
Small moleculeHIV proteasenot yet gradedNo reviewed efficacy summary in this indication
Bictegravir (Biktarvy)ApprovedSmall moleculeHIV integraseReliable signal
NCT03110380: Participants with HIV-1 RNA ≥50 copies/mL at week 48 (FDA snapshot): 0.4% with B/F/TAF vs 1.1% with dolutegravir plus emtricitabine/tenofovir alafenamide; difference -0.7% (95% CI -2.8% to 1.0%), inside the pre-specified 4% non-inferiority margin (CT.gov posted analysis).
NCT02607956: Week 48 HIV-1 RNA <50 copies/mL: 89.4% B/F/TAF vs 92.9% DTG + F/TAF; difference -3.5 percentage points (95.002% CI -7.9 to 1.0); prespecified non-inferiority margin 12%.
Bictegravir / Lenacapavir (Bixlenvo)ApprovedSmall moleculeHIV integrase, HIV capsidPartial signal
NCT05502341: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results).
Cabotegravir (Apretude)ApprovedSmall moleculeHIV integraseReliable signal
NCT02720094: Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.): Cabotegravir 13/2280 vs TDF/FTC 39/2281
Cabotegravir / Rilpivirine (Cabenuva)ApprovedSmall moleculeHIV integrase, HIV reverse transcriptaseWeak signal
NCT03299049: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results).
NCT02938520: Virologic failure (HIV-1 RNA >=50 copies/mL, FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 4 weeks vs abacavir/dolutegravir/lamivudine: 2.1% vs 2.5%, adjusted difference -0.4% (95% CI -2.8 to 2.1); non-inferior against the 6% margin (CT.gov posted results).
Darunavir (Prezista)ApprovedSmall moleculeHIV proteasePartial signal
NCT00110877: HIV RNA <400 copies/mL at Week 48 (per-protocol population): darunavir-ritonavir 77% (220/286) vs lopinavir-ritonavir 68% (199/293); estimated difference 9% (95% CI 2-16).
Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component))ApprovedSmall moleculeHIV integraseReliable signal
NCT01263015: Week 48 HIV-1 RNA <50 c/mL: 88% with dolutegravir plus abacavir/lamivudine vs 81% with Atripla; difference 7.3 percentage points (95% CI 2.3 to 12.2; p=0.003).
NCT01449929: Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) at Week 48 (Week 48): DTG 50 mg QD 90% vs DRV 800 mg + RTV 100 mg QD 83%
Doravirine (Pifeltro)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT02403674: Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033).
NCT02275780: Week 48 HIV-1 RNA <50 copies/mL: 83.8% doravirine vs 79.9% darunavir/ritonavir; treatment difference 3.913 percentage points (95% CI -1.590 to 9.415), non-inferiority margin -10 percentage points.
Doravirine / Islatravir (Idvynso)ApprovedSmall moleculeHIV reverse transcriptase, HIV-1 Reverse TranscriptasePartial signal
NCT05630755: HIV-1 RNA at or above 50 copies/mL at Week 48 (FDA Snapshot), switch to doravirine/islatravir (n=342) vs staying on bictegravir/emtricitabine/tenofovir alafenamide (n=171): 1.5% vs 0.6%; risk difference 0.88 percentage points (95% CI -1.86 to 2.90), non-inferiority p=0.003 against a 4-point margin (CT.gov posted results).
NCT04233879: Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 (Week 48): Group 1: DOR/ISL 88.9% vs Group 2: BIC/FTC/TAF 88.3%
Elvitegravir (Stribild)ApprovedSmall moleculeHIV integrasePartial signal
NCT01095796: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1%
Emtricitabine (Emtriva)ApprovedSmall moleculeHIV reverse transcriptasePartial signal
NCT00112047: Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants
Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada)ApprovedSmall moleculeHIV reverse transcriptasePartial signal
NCT00323544: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm.
Etravirine (Intelence)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT00254046: Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005
NCT00255099: Confirmed viral load <50 copies/mL at Week 24 (intention to treat): etravirine (TMC125) 62% (183/295) vs placebo 44% (129/296); difference 18% (95% CI 11-26; p=0.0003).
Fostemsavir (Rukobia)ApprovedSmall moleculeHIV gp120Partial signal
NCT02362503: Mean Change in Logarithm to the Base 10 (log10) HIV-1 Ribonucleic Acid (RNA) From Day 1 at Day 8-Randomized Cohort (Day 1 and Day 8): Randomized Cohort-fostemsavir 600 mg BID -0.791 Log10 copies per milliliter (c/mL) (95% CI -0.885 to -0.698) vs Randomized Cohort-Placebo -0.166 Log10 copies per milliliter (c/mL) (95% CI -0.326 to -0.007)
NCT01384734: HIV-1 RNA < 50 copies/mL at Week 24: fostemsavir 400 mg BID 80% (95% CI 66.3 to 90), 800 mg BID 69% (54.6 to 81.7), 600 mg QD 76% (62.5 to 87.2) and 1200 mg QD 72% (57.5 to 83.8) vs the atazanavir/ritonavir reference arm 75% (60.4 to 85.7).
Ibalizumab (Trogarzo)ApprovedMonoclonal antibodyCD4 receptorWeak signal
NCT02475629: Efficacy: Proportion of Participants Achieving a Viral Load Reduction of at Least 0.5 Log 10: ITT-MEF (Day 14): Open-Label Ibalizumab Plus OBR 82.5% (95% CI 67.72% to 92.66%)
Lenacapavir (Sunlenca)ApprovedSmall moleculeHIV capsidPartial signal
NCT04150068: Percentage of Participants in Cohort 1 Achieving a Reduction of ≥ 0.5 log10 Copies/mL in Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) From Baseline to the End of Functional Monotherapy Period (Baseline up to Day 1 SC Visit (14 days after the first dose of oral lencapavir) or Day 15): Cohort 1A: Lenacapavir 87.5 percentage of participants | Cohort 1B: Placebo to Lenacapavir 16.7 percentage of participants
NCT04143594: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm (Week 54): Group 1: SC LEN+(F/TAF→ TAF) 90.4% vs Group 2: SC LEN + (F/TAF → BIC) 84.9% vs Group 3: Oral LEN + F/TAF 84.6% vs Group 4: B/F/TAF 92.0%; p=0.7178 (Group 1: SC LEN+(F/TAF→ TAF) vs Group 4: B/F/TAF), p=0.3900 (Group 2: SC LEN + (F/TAF → BIC) vs Group 4: B/F/TAF), p=0.3797 (Group 3: Oral LEN + F/TAF vs Group 4: B/F/TAF) missed
Lenacapavir (Yeztugo)ApprovedSmall moleculeHIV capsidReliable signal
NCT04925752: HIV incidence: 0.10 per 100 PY on twice-yearly lenacapavir (2 infections) vs background incidence 2.37 per 100 PY (IRR 0.04; 95% CI 0.01-0.18; P<0.001) and vs F/TDF 0.93 per 100 PY (IRR 0.11; 95% CI 0.02-0.51; P=0.002) (PURPOSE 2, NEJM 2025).
NCT04994509: HIV incidence: 0 infections in 2,134 on twice-yearly lenacapavir (0 per 100 PY; 95% CI 0.00-0.19) vs background incidence 2.41 per 100 PY (IRR 0.00; 95% CI 0.00-0.04; P<0.001) and vs F/TDF 1.69 per 100 PY (IRR 0.00; 95% CI 0.00-0.10; P<0.001) (PURPOSE 1, NEJM 2024).
Lonapegsomatropin (Skytrofa)
Approved(overall)
Protein / enzyme therapeuticGrowth hormone receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Maraviroc (Selzentry / Celsentri)ApprovedSmall moleculeCCR5 co-receptorPartial signal
NCT00098293: Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population (Week 48): Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL) — Less than 400 copies/mL: 61.5%; Less than 50 copies/mL: 55.8% | Maraviroc Twice Daily + CBV (DB) — Less than 400 copies/mL: 70.6%; Less than 50 copies/mL: 65.3% vs Efavirenz Once Daily + CBV (DB) — Less than 400 copies/mL: 73.1%; Less than 50 copies/mL: 69.3%
Raltegravir (Isentress)ApprovedSmall moleculeHIV integraseReliable signal
NCT00293254: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3)
NCT00293267: Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.7% (95% CI 71.8 to 82.9) vs Placebo + OBT 41% (95% CI 32 to 50.5)
Rilpivirine (Edurant)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT00540449: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%.
NCT00543725: Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies Per mL) at Week 48 (Week 48): TMC278 — Responder: 291/340; Virologic failure: 24/340; Death: 1/340; Discontinued due to AE: 8/340; Discontinued due to other reason than AE: 16/340 vs Efavirenz — Responder: 276/338; Virologic failure: 18/338; Death: 3/338; Discontinued due to AE: 21/338; Discontinued due to other reason than AE: 20/338
Somatrogon (NGENLA)
Approved(overall)
Protein / enzyme therapeuticGrowth hormone receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Tenofovir Alafenamide / Emtricitabine (Descovy)ApprovedSmall moleculeHIV reverse transcriptaseReliable signal
NCT02842086: Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564)
Tenofovir Disoproxil Fumarate (Viread)ApprovedSmall moleculeHIV reverse transcriptase (RT)Partial signal
NCT00528957: Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Week 48 (48 weeks): Tenofovir DF 83.3 percentage of participants | Stavudine or Zidovudine 91.8 percentage of participants | All TDF 85.4 percentage of participants missed
NCT00352053: Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA (Baseline to 24 Weeks): Tenofovir DF -1.58 log10 copies/mL (IQR -2.15 to -0.27) | Placebo -1.549 log10 copies/mL (IQR -2.36 to -0.34) missed
Tesamorelin (Egrifta WR)ApprovedPeptideGrowth hormone-releasing hormone (GHRH) receptorPartial signal
NCT00608023: Changes From Baseline in Fasting Blood Glucose at Week 52 (Baseline and Week 52): Tesamorelin 52 Weeks 0 mg/dL (Standard Deviation 16) missed
Tipranavir (Aptivus)ApprovedSmall moleculeHIV proteasePartial signal
NCT00144170: Treatment Response at Week 48 (after 48 weeks of treatment): Tipranavir(TPV)/Low Dose Ritonavir(r) 34.5% vs Comparator Protease Inhibitor(CPI)/Low Dose Ritonavir(r) 15%
NCT00054717: Treatment Response at Week 48 (At week 48): Tipranavir(TPV)/Low Dose Ritonavir(r) 33.8% vs Comparitor Protease Inhibitor(CPR)/Low Dose Ritonavir(r) 16.2%
ACC017Phase 3Small moleculeHIV integrasePartial signal
NCT06719310: The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29.
Albuvirtide (Aikening)Phase 3PeptideHIV gp41Partial signal
NCT02369965: Primary, HIV-1 RNA <50 copies/mL at week 48 (mITT, interim analysis with 46 albuvirtide and 50 control patients at week 48): 80.4% (37/46) albuvirtide + lopinavir/ritonavir vs 66.0% (33/50) NRTIs + lopinavir/ritonavir; difference 14.4% (95% CI -3.0% to 31.9%) against a prespecified non-inferiority margin of -12%, met.
AlimatravirPhase 3Small moleculeHIV-1 Reverse TranscriptaseWeak signal
NCT06045507: Primary outcomes, safety (no formal efficacy test): participants with at least one adverse event 62/101 (3 mg), 69/101 (6 mg) and 66/99 (12 mg) monthly MK-8527 vs 31 on placebo; discontinuation due to an adverse event 0, 2 and 1 vs 2 (CT.gov posted results).
Azvudine (FNC)Phase 3Small moleculeHIV reverse transcriptasePartial signal
NCT04109183: 符合方案集(PPS)阿兹夫定 2 mg 组、阿兹夫定 3 mg 组、阿兹夫定 4 mg 组和 3TC 组结果分别为 97.2%、100%、100% 和 97.5%。经卡方分析各组之间无显著统计学差异(P>0.05)
Dapivirine (Dapivirine Vaginal Ring)Phase 3Small moleculeHIV reverse transcriptaseReliable signal
NCT01617096: HIV-1 seroconversion: 71/1313 dapivirine vs 97/1313 placebo; incidence 27% lower with dapivirine (95% CI 1 to 46; P = 0.046), 37% lower after exclusion of two low-adherence sites (P = 0.007).
IslatravirPhase 3Small moleculeHIV-1 Reverse Transcriptasenot yet gradedNo reviewed efficacy summary in this indication
Islatravir / LenacapavirPhase 3Small moleculeHIV-1 Reverse Transcriptase, HIV capsidnot yet gradedNo reviewed efficacy summary in this indication
SemzuvolimabPhase 3Monoclonal antibodyCD4 receptorWeak signalNo reviewed efficacy summary in this indication
Somatropin (Jintropin)
Phase 3(overall)
Biologic (subtype unspecified)Growth hormone receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
TeropavimabPhase 3Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
ZinlirvimabPhase 3Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
Elsulfavirine (Elpida)Phase 2/3Small moleculeHIV reverse transcriptasePartial signalNo reviewed efficacy summary in this indication
LeronlimabPhase 2/3Monoclonal antibodyCCR5 co-receptorWeak signal
NCT02483078: Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period (From baseline visit to week 1 visit): PRO 140 — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 64%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 36% | Placebo — With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 23%; Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline: 77%
NCT02859961: Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure (From T1 (first treatment administration) to week 48 (T48).): Part 1 - 350 mg Weekly Injections of PRO 140, Group A 23% | Part 1 - 525 mg Weekly Injections of PRO 140, Group B 43% | Part 1 - 700 mg Weekly Injections of PRO 140, Group C 45%
UlonivirinePhase 2/3Small moleculeHIV reverse transcriptaseWeak signalFeatured results are safety only in this race
10-1074Phase 2Monoclonal antibodyHIV envelopeWeak signalFeatured results are safety only in this race
3BNC117Phase 2Monoclonal antibodyHIV envelopePartial signal
NCT03041012: Co-primary 1, plasma HIV-1 RNA decay rate, ART+romidepsin+3BNC117 vs ART only: daily decay 16.9% (95% CI -27.3% to -4.93%) vs 10.0% (95% CI -14.9% to -4.86%) from day 10 to 24 (P=0.048); comparable from day 0 to 10 and day 24 to 90, met. Co-primary 2, change in intact HIV-1 provirus frequency from baseline to day 365: all groups decreased, with no significant differences between the groups, missed.
CL-197Phase 2Small moleculeHIV reverse transcriptaseWeak signalNo reviewed efficacy summary in this indication
DezecapavirPhase 2Small moleculeHIV capsidPartial signal
NCT06039579: Monotherapy, VH4011499: Maximum Change From Baseline (Day 1) in Plasma HIV-1 RNA log10 (From Baseline (Day 1) and up to Day 11): Part 1b: VH4011499 Dose Level 1 — Baseline (Day 1): 5.001 log10 c/mL (Standard Deviation 0.7304); Maximum change compared to Baseline (Day 1): -1.834 log10 c/mL (Standard Deviation 0.5141) | Part 1b: VH4011499 Dose Level 2 — Baseline (Day 1): 4.339 log10 c/mL (Standard Deviation 0.6185); Maximum change compared to Baseline (Day 1): -1.797 log10 c/mL (Standard Deviation 0.4544) | Part 2b: VH4011499 Pre-specified Dose — Baseline (Day 1): 4.96 log10 c/mL (Standard Deviation 0.7288); Maximum change compared to Baseline (Day 1): -2.165 log10 c/mL (Standard Deviation 0.431) vs Matching Placebo for VH4011499 — Baseline (Day 1): 4.714 log10 c/mL (Standard Deviation 0.7736); Maximum change compared to Baseline (Day 1): -0.176 log10 c/mL (Standard Deviation 0.1969)
EnvafolimabPhase 2Monoclonal antibodyPD-L1Weak signalNo reviewed efficacy summary in this indication
HTI Vaccine (ChAdOx1.HTI / MVA.HTI)Phase 2VaccineHIV-1 conserved epitopes (HTI)Partial signal
NCT03204617: Primary, safety (grade 3 or 4 local and systemic reactions; no formal efficacy test): adverse events were mostly mild and transient, with no related serious adverse events. Secondary: HTI vaccines induced strong, broad CD4 and CD8 T-cell responses; all participants had detectable viral rebound during treatment interruption.
LipovirtidePhase 2PeptideHIV gp41Partial signalNo reviewed efficacy summary in this indication
LotivibartPhase 2Monoclonal antibodyHIV envelopeWeak signal
NCT04871113: Maximum Decline From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Levels - Monotherapy Phase (Baseline (Day 1) and up to Day 84 or end of Monotherapy Phase): Part 1:GSK3810109A 40milligram(mg)/Kilogram Intravenously (IV) — Baseline (Day 1): 12258.5 Copies per milliliter (copies/mL) (range 1351 to 173710); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12014.5 Copies per milliliter (copies/mL) (range -171577 to -1312) | Part 1: GSK3810109A 280 mg IV — Baseline (Day 1): 30833 Copies per milliliter (copies/mL) (range 5938 to 104585); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -26826.5 Copies per milliliter (copies/mL) (range -103583 to -5899) | Part 2: GSK3810109A 700 mg IV — Baseline (Day 1): 25466 Copies per milliliter (copies/mL) (range 7180 to 110387); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -25966 Copies per milliliter (copies/mL) (range -107218 to -6944) | Part 2: GSK3810109A 70 mg IV — Baseline (Day 1): 25689.5 Copies per milliliter (copies/mL) (range 7225 to 683576); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -14720.5 Copies per milliliter (copies/mL) (range -197793 to -4382) | Part 2: GSK3810109A 700 mg Subcutaneously (SC) — Baseline (Day 1): 23146 Copies per milliliter (copies/mL) (range 131 to 181078); Maximum decline from baseline (up to Day 84/end of Monotherapy Phase): -12584 Copies per milliliter (copies/mL) (range -178423 to -69)
TMB-365 / TMB-380Phase 2CombinationCD4; HIV envelopenot yet gradedNo reviewed efficacy summary in this indication
TrosunilimabPhase 2Monoclonal antibodyα4β7 integrinPartial signalFeatured results are safety only in this race
VesatolimodPhase 2Small moleculeToll-like receptor 7 (TLR7) (agonist)Weak signalFeatured results are safety only in this race
VH4004280 (VH-280)Phase 2Small moleculeHIV capsidPartial signal
NCT06039579: Monotherapy, VH4004280: Maximum Change From Baseline (Day 1) in Plasma HIV-1 Ribonucleic Acid (RNA) log10 (From Baseline (Day 1) and up to Day 11): Part 1a: VH4004280 Dose Level 1 — Baseline (Day 1): 5.004 log10 c/mL (Standard Deviation 0.4592); Maximum change compared to Baseline (Day 1): -1.056 log10 c/mL (Standard Deviation 0.4567) | Part 1a: VH4004280 Dose Level 2 — Baseline (Day 1): 4.923 log10 c/mL (Standard Deviation 0.5428); Maximum change compared to Baseline (Day 1): -1.391 log10 c/mL (Standard Deviation 0.6986) | Part 2a: VH4004280 Pre-specified Dose — Baseline (Day 1): 4.866 log10 c/mL (Standard Deviation 0.7696); Maximum change compared to Baseline (Day 1): -1.983 log10 c/mL (Standard Deviation 0.2171) vs Matching Placebo for VH4004280 — Baseline (Day 1): 4.636 log10 c/mL (Standard Deviation 0.6641); Maximum change compared to Baseline (Day 1): -0.07 log10 c/mL (Standard Deviation 0.0574)
VH4524184Phase 2Small moleculeHIV integrasePartial signal
NCT06214052: Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): VH4524184 Dose 1 -1.17 Copies per milliliter (copies/mL) (Standard Deviation 0.46) | VH4524184 Dose 2 -2.15 Copies per milliliter (copies/mL) (Standard Deviation 0.254) | VH4524184 Dose 3 -2.31 Copies per milliliter (copies/mL) (Standard Deviation 0.463) vs Placebo -0.28 Copies per milliliter (copies/mL) (Standard Deviation 0.37)
JL18008Phase 1/2Protein / enzyme therapeuticIL-7 receptorWeak signalNo reviewed efficacy summary in this indication
LP-98Phase 1/2PeptideHIV gp41Partial signalNo reviewed efficacy summary in this indication
AGT103-TPhase 1Gene therapy / editingHIV proviral reservoir / autologous T cellsWeak signalFeatured results are safety only in this race
AinuovirinePhase 1Small moleculeHIV reverse transcriptaseWeak signalFeatured results are safety only in this race
AV000103A (ICVAX)Phase 1VaccineHIV antigensWeak signalFeatured results are safety only in this race
BNT168Phase 1VaccineHIV antigensnot yet gradedNo reviewed efficacy summary in this indication
BNT351Phase 1Monoclonal antibodyHIV envelopenot yet gradedNo reviewed efficacy summary in this indication
CPT31Phase 1PeptideHIV gp41Weak signalFeatured results are safety only in this race
MGD014Phase 1Multispecific antibodyHIV envelope gp120 x CD3Weak signalFeatured results are safety only in this race
MGD020Phase 1Multispecific antibodyHIV envelope gp41 x CD3Weak signalFeatured results are safety only in this race

Large race: only the 63 furthest-along competitors are listed; 8 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

No upcoming readouts on record for this asset.